CLOs on the Move

EnteraTech

www.enteratech.com

 
EnteraTech is a Hilliard, OH-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Inimmune

Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.

Epigentek

Epigentek is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Theralogix

Theralogix is a Holmes, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Verastem

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay but improve the lives of patients diagnosed with cancer. Because for us, it`s personal. Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. We believe that empowering employees is what makes them truly care about the important work they do.

Miraculins

Miraculins is a pre-revenue biotechnology company that acquires, develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The Company specializes in the development and manufacturing of medical devices and has been successfully accessing capital on the public markets as required to finance its operations to date. It is currently preparing for transition to a commercialization phase. Miraculins began as a research and development company in 2002, with a focus on biomarker discovery. In June of 2008, the company shifted its focus to diagnostic asset development where it began to in-license and acquire diagnostic and risk assessment technologies that had completed early stage research and addressed significant unmet medical needs in the U.S., Canada, and global markets.